Welcome to our dedicated page for Fresenius Medical Care SEC filings (Ticker: FMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Fresenius Medical Care's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Fresenius Medical Care's regulatory disclosures and financial reporting.
Fresenius Medical Care AG furnished a Form 6-K announcing its third quarter results for the period ended September 30, 2025. The submission includes a press release (Exhibit 99.1) and accompanying financial figures (Exhibit 99.2).
The company highlights non-GAAP measures alongside IFRS results, including EBITDA, free cash flow, net leverage ratio (net debt to adjusted EBITDA), constant-currency metrics, and results adjusted for special items, with reconciliations provided in the exhibits. The exhibits are furnished, not filed.